AXSOME THERAPEUT. DL-0001 WKN: A2AA7B ISIN: US05464T1043 Kürzel: AXSM Forum: Aktien Thema: Hauptdiskussion

Axsome ist mehrfach ausgezeichnet worden. Günstig einsammeln 😉

Ist die Bude tot? Geht nur Abwärts 🤔

Sehen wir hier diese Woche noch Jahrestief? Dann wird es interessant. Gibt es da keine Bodenbildung geht es auf 50 Dollar

Ich sehe den Chart seit über einen Jahr und der zeigt halt nichts gutes. Von 110 auf unter 50 oder siehst was anderes

Ich kenne Axsome seit 3€ Kurs... Die Richtung ist also richtig... Auch wenn wir nicht mehr bei 100€ sind!!!

Junge...Guck dir den 3 Jahreschart an - dann siehst du welche Richtung die Aktie kennt. Man man man, überall diese Reddit Jünger.

50 Euro. Die Aktie kennt nur eine Richtung

Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update https://www.globenewswire.com/news-release/2021/03/01/2184108/0/en/Axsome-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results-and-Provides-Business-Update.html Axsome: 4Q Earnings Snapshot https://www.sfchronicle.com/business/article/Axsome-4Q-Earnings-Snapshot-15987806.php

📌

Zeit das es wieder nach oben geht, die letzten Tage wahren hart

👍👍

Axsome says it remains on track to submit AXS-05 marketing application to the FDA https://newsfilter.io/a/361877da089094d55c8cd738862b69e1 • Axsome Therapeutics (AXSM +0.1%) announces that it remains on track and is in the process of submitting a New Drug Application for AXS-05 in major depressive disorder to the U.S. FDA. • Axsome initiated its ACCORD study, a Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AXS-05 in the treatment of Alzheimer’s disease agitation, in December last year. • AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. • The company had also announced positive results from the open-label Phase 2 COMET-SI trial of AXS-05 in patients with major depressive disorder who have suicidal ideation, last month

👍👍

Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine https://www.globenewswire.com/news-release/2020/12/31/2152004/0/en/Axsome-Therapeutics-Announces-Positive-Efficacy-and-Safety-Results-from-the-Phase-3-MOVEMENT-Long-Term-Trial-of-AXS-07-in-the-Acute-Treatment-of-Migraine.html Over 21,000 migraine attacks treated with AXS-07 Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hours Achieved durable relief, with approximately 85% of patients free from rescue medication use over 48 hours Long-term safety profile consistent with previously completed controlled trials NDA on track for submission in 1Q 2021

Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer's Disease Agitation https://www.benzinga.com/node/18975732 ACCORD is the second pivotal trial of AXS-05 in Alzheimer's disease agitation No treatments are currently approved for Alzheimer's disease agitation

Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation https://www.globenewswire.com/news-release/2020/12/08/2141143/0/en/Axsome-Therapeutics-Announces-Positive-Results-from-the-COMET-SI-Trial-of-AXS-05-in-Patients-with-Major-Depressive-Disorder-Who-Have-Suicidal-Ideation.html 68% reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4 Resolution of suicidal ideation achieved by 60% of patients by Week 1, and 78% by Week 4 Effects consistent with new integrated data from AXS-05 controlled trials demonstrating reduction in MADRS Suicidality Item score versus control, at Week 1 (p=0.001) Rapid and substantial improvement in functioning achieved by 51% of patients at Week 1 and 77% of patients at Week 6 (Sheehan Disability Scale) ...